DuPont de Nemours, Inc. (NYSE: DD)

Sector: Basic Materials Industry: Specialty Chemicals CIK: 0001666700
ROIC (Qtr) 0.02
Total Debt (Qtr) 3.19 Bn
Revenue Growth (1y) (Qtr) 0.24
Add ratio to table...

About

DuPont de Nemours, Inc., often referred to as DuPont, is a global innovation leader that operates in the chemical industry, providing diverse science and expertise to help customers advance their best ideas and deliver essential innovations in various markets, such as electronics, transportation, construction, water, healthcare, and worker safety. The company was established in 2015, following the merger of The Dow Chemical Company and E. I. du Pont de Nemours and Company, and is based in Delaware, with subsidiaries in around 50 countries and manufacturing...

Read more

Investment thesis

Bull case

  • The company’s EBITDA expanded by 6% with a 100‑basis‑point margin lift, driven by disciplined cost controls, Kaizen events, and AI‑enabled productivity initiatives. This operational discipline is reinforced by a strong free‑cash‑flow conversion projected above 90% in 2026, giving management a solid runway for both capital deployment and shareholder returns. The margin expansion aligns with a broader industry shift toward high‑margin specialty applications, positioning DuPont to capture a larger share of the earnings pie as it continues to trim low‑margin business lines. The combination of steady cash flow and a proven track record of margin improvement suggests that the company can sustain its profitability trajectory even if macro‑economic headwinds intensify.
  • DuPont’s innovation engine remains a key differentiator, having launched 125 new products in 2025 that generated over $2 billion in sales and a vitality index of approximately 30%. The vitality index not only reflects a healthy share of new‑product revenue but also delivers roughly 145 basis‑points of margin lift relative to the company average, underscoring the premium associated with newer offerings. As the portfolio tilts toward higher‑margin items, the company can command stronger pricing power, especially in the medical‑device and water‑filtration segments where demand is driven by demographic and regulatory forces. Continued investment in R&D, coupled with a disciplined product‑cycle management, will keep the pipeline robust and help maintain the upward pressure on both top‑line growth and margin quality.
  • The divestiture of the Aramis business, slated to close in early 2026, will net roughly $1 billion after taxes, of which $500 million has already been deployed via an accelerated share‑repurchase. The remaining proceeds are earmarked for opportunistic M&A, particularly in healthcare, which has attracted a wealth of fragmented, undervalued assets. This strategic reallocation signals a clear intent to consolidate DuPont’s core capabilities and to grow organically through acquisitions that fit well with its existing product platforms. The dual focus on shareholder return and strategic expansion provides a balanced framework that can enhance long‑term value without over‑leveraging the balance sheet.
  • DuPont’s secular growth story is underpinned by mid‑single‑digit expansion in healthcare and water, sectors that benefit from aging demographics, regulatory mandates, and infrastructure investment. The automotive segment, while flat overall, is poised for outperformance through electrification, and aerospace demand remains resilient, providing a counterbalance to the cyclical nature of construction‑driven building‑technologies sales. Coupled with a robust order‑book visibility—about 50% of orders booked each quarter and 80% monthly—management can translate this demand into consistent revenue growth. Such momentum mitigates the risk of sales volatility and supports the projected 3% organic growth for 2026.
  • Capital allocation remains a cornerstone of DuPont’s value‑creation thesis, with a $2 billion share‑repurchase authorization already partially utilized and dividends tied to a targeted payout ratio. The company’s free‑cash‑flow generation is expected to be strong, ensuring that shareholder returns can be maintained even if M&A activity slows or market conditions deteriorate. This conservative yet proactive approach to capital deployment preserves liquidity, allowing the firm to seize attractive acquisition targets as they arise without compromising its financial flexibility.
Read more

Bear case

  • Despite the upside, the industrials segment remains a weak link, reporting a 3% decline in Q4 sales and low‑single‑digit growth forecasts for the year. The segment’s performance is heavily reliant on aerospace and automotive sub‑verticals, both of which are susceptible to cyclical demand swings and raw‑material cost volatility. A sustained downturn in construction or a slowdown in the U.S. automotive market could compress the already thin industrial margins and negate the productivity gains the company has touted. Therefore, the industrial segment presents a potential drag on the overall top‑line and margin trajectory if macro‑economic conditions do not improve as expected.
  • The company’s reliance on new product sales, while a source of margin lift, also introduces a sustainability risk. The vitality index of 30% is impressive, but the underlying mix—replacement versus growth—remains unclear. If the 30% of sales from recent launches is predominantly replacement, future revenue growth could stall once the initial enthusiasm wanes. Additionally, the high margin contribution from new products may not be fully replicable across all portfolio areas, raising the question of whether DuPont can consistently deliver similar performance in subsequent product cycles.
  • The Aramis divestiture, though providing immediate cash, carries hidden integration and post‑transaction risks. The separation process can incur unforeseen liabilities, transition costs, and regulatory hurdles that could offset the expected proceeds. With only half of the $1 billion used for an accelerated share‑repurchase, the remaining capital is earmarked for M&A, yet there is no guarantee that suitable targets will materialize or that acquisitions will close at the anticipated valuations. If the company over‑spends on M&A or fails to achieve expected synergies, the net benefit could diminish, impacting both cash flow and shareholder returns.
  • Supply‑chain disruptions were hinted at during the Q&A, notably a change in the shelter business’s distributor joint venture that negatively impacted Asia‑Pacific sales. While management downplayed the event as temporary, it underscores DuPont’s vulnerability to partner‑related risks that can affect inventory levels and pricing power. In addition, the company’s exposure to commodity price swings—especially for chemical feedstocks used in water and healthcare products—was not fully addressed. Rising material costs could erode the margin expansion that the company has achieved, particularly if price increases outpace revenue growth.
  • The company’s ESG and regulatory posture remains largely opaque, raising concerns about potential future compliance costs. Water filtration and medical‑device segments are subject to stringent regulatory regimes, and any tightening of standards could impose additional testing, certification, or product redesign requirements. Such regulatory changes could delay product launches, increase capital expenditures, or even lead to product recalls, all of which would negatively affect profitability and cash flow.
Read more

Restructuring Plan Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer comparison

Companies in the Specialty Chemicals
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 BGLC BioNexus Gene Lab Corp - - - -
2 APD Air Products & Chemicals, Inc. - - - 0.25 Bn
3 LIN Linde Plc - - - 25.19 Bn
4 MTX Minerals Technologies Inc - - - 0.96 Bn
5 ASH Ashland Inc. - - - 1.39 Bn
6 NNUP Nocopi Technologies Inc/Md/ - - - -
7 FUL Fuller H B Co - - - 2.02 Bn
8 OEC Orion S.A. - - - 0.98 Bn